{
    "id": "medical_genetics-022",
    "question": "The pattern of inheritance shown by glucose-6-phosphate dehydrogenase (G6PD) deficiency is:",
    "options": {
        "A": "autosomal dominant.",
        "B": "autosomal recessive.",
        "C": "X-linked dominant.",
        "D": "X-linked recessive."
    },
    "answer": "D",
    "predict": "To solve this question, let's analyze the given documents and think step-by-step. Step 1: Understand the definition of G6PD deficiency G6PD deficiency is an abnormality in the hexose monophosphate shunt pathway of glycolysis that results in the depletion of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and the inability to regenerate reduced glutathione. Step 2: Identify the gene location The gene for G6PD deficiency is on the X chromosome. Step 3: Recall the pattern of inheritance Since the gene is located on the X chromosome, we need to consider the pattern of inheritance of X-linked disorders. Step 4: Analyze the options A. Autosomal dominant: This pattern of inheritance involves a dominant allele that can cause the condition if present in one copy of the chromosome. However, G6PD deficiency is not mentioned to be dominant in the documents. B. Autosomal recessive: This pattern of inheritance involves two copies of a recessive allele to cause the condition. However, G6PD deficiency is mentioned to be X-linked, not autosomal. C. X-linked dominant: This pattern of inheritance involves a dominant allele on the X chromosome that can cause the condition if present in one copy of the chromosome. However, the documents do not mention that the condition is dominant. D. X-linked recessive: This pattern of inheritance involves a recessive allele on the X chromosome that can cause the condition if an individual has two copies of the recessive allele (one from each X chromosome). Since females have two X chromosomes, they can be carriers of the condition, while males, who have only one X chromosome, will express the condition if they have the recessive allele. Conclusion: Given that the gene for G6PD deficiency is on the X chromosome and considering the pattern of inheritance of X-linked disorders, the correct answer is: {\"step_by_step_thinking\": \"The gene for G6PD deficiency is located on the X chromosome, and the pattern of inheritance of X-linked disorders involves a recessive allele that will express the condition if an individual has two copies of the recessive allele, one from each X chromosome.\", \"answer_choice\": \"D\"}",
    "snippets": [
        {
            "id": "Pediatrics_Nelson_3225",
            "title": "Pediatrics_Nelson",
            "content": "Available @ StudentConsult.com Etiology. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an abnormality in the hexose monophosphate shunt pathway of glycolysis that results in the depletion of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and the inability to regenerate reduced glutathione. When a patient with G6PD is exposed to significant oxidant stress, hemoglobin is oxidized, forming precipitates of sulfhemoglobin (Heinz bodies), which are visible on specially stained preparations. The gene for G6PD deficiency is on the X chromosome. The severity of hemolysis depends on the enzyme variant. In many G6PD variants, the enzymes become unstable with aging of the RBC and cannot be replaced because the cell is anucleated. Older cells are most susceptible to oxidant-induced hemolysis. In other variants, the enzyme is kinetically abnormal."
        },
        {
            "id": "Obstentrics_Williams_7720",
            "title": "Obstentrics_Williams",
            "content": "Glucose-6-phosphate dehydrogenase (G6PD) deiciency is complex because there are more than 400 known enzyme variants. he most common are caused by a base substitution that leads to an amino acid replacement and a broad range of phenotypic severity (Luzzatto, 2015; Puig, 2013). In the homozygous or A variant, both X chromosomes are afected, and erythrocytes are markedly deicient in G6PD activity. Approximately 2 percent of African-American women are afected, and the heterozygous variant is found in 10 to 15 percent (Mockenhaupt, 2003). In both instances, random X-chromosome inactivation-yonization-results in variable enzyme activity."
        },
        {
            "id": "InternalMed_Harrison_8246",
            "title": "InternalMed_Harrison",
            "content": "CHAPTEr129 Hemolytic Anemias and Anemia Due to Acute Blood Loss FIGURE 129-6 Epidemiology of glucose 6-phosphate dehydrogenase (G6PD) deficiency throughout the world. The different shadings indicate increasingly high levels of prevalence, up to about 20%; the different colored symbols indicate individual genetic variants of G6PD, each one having a different mutation. (From L Luzzatto et al, in C Scriver et al [eds]: The Metabolic & Molecular Bases of Inherited Disease, 8th ed. New York, McGraw-Hill, 2001.) bilirubin, indicating that there is also extravascular hemolysis. The most serious threat from AHA in adults is the development of acute renal failure (this is exceedingly rare in children). Once the threat of acute anemia is over and in the absence of comorbidity, full recovery from AHA associated with G6PD deficiency is the rule."
        },
        {
            "id": "InternalMed_Harrison_8235",
            "title": "InternalMed_Harrison",
            "content": "abnormalities of redox metabolism glucose 6-phosphate dehydrogenase (g6pd) deficiency G6PD is a housekeeping enzyme critical in the redox metabolism of all aerobic cells (Fig. 129-1). In red cells, its role is even more critical, because it is the only source of NADPH, which directly and via glutathione (GSH) defends these cells against oxidative stress (Fig. 129-5). G6PD deficiency is a prime example of an HA due to interaction between FIGURE 129-5 Diagram of redox metabolism in the red cell. 6PG, 6-phosphogluconate; G6P, glucose 6-phosphate; G6PD, glucose 6-phosphate dehydrogenase; GSH, reduced glutathione; GSSG, oxidized glutathione; Hb, hemoglobin; MetHb, methemoglobin; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate."
        },
        {
            "id": "Biochemistry_Lippincott_1922",
            "title": "Biochemistry_Lippinco",
            "content": "Diagnosis: JF has glucose 6-phosphate dehydrogenase (G6PD) deficiency, an X-linked disorder that causes hemolysis (RBC lysis). Treatment: G6PD deficiency can result in a hemolytic anemia in affected individuals exposed to oxidative agents. JF will be switched to a different antibiotic. He will be advised that he is susceptible to certain drugs (for example, sulfa drugs), foods (fava or broad beans), and certain chemicals (for example, naphthalene), and must avoid exposure to them. Prognosis: In the absence of exposure to oxidative agents, G6PD deficiency does not cause mortality or significant morbidity. Case-Related Questions: Choose the ONE best answer. Q1. G6PD catalyzes the regulated step in the pentose phosphate pathway. Which of the following statements concerning G6PD and the pentose phosphate pathway is correct? A. Deficiency of G6PD occurs only in RBC. B. Deficiency of G6PD results in an inability to keep glutathione in its functional, reduced form."
        },
        {
            "id": "Pathology_Robbins_2716",
            "title": "Pathology_Robbins",
            "content": "Red cells are constantly exposed to both endogenous and exogenous oxidants, which are normally inactivated by reduced glutathione (GSH). Abnormalities affecting enzymes responsible for the synthesis of GSH leave red cells vulnerable to oxidative injury and hemolysis. By far the most common of these conditions is glucose-6-phosphate dehydrogenase (G6PD) deficiency. The G6PD gene is on the X chromosome. More than 400 G6PD variants have been identified, but only a few are associated with disease. One is G6PD A\u2212 , which is carried by approximately 10% of black males in the United States. G6PD A\u2212 has a normal enzymatic activity but a decreased half-life. Because red cells do not synthesize proteins, older G6PD A\u2212 red cells become progressively deficient in enzyme activity and GSH. This in turn renders older red cells more sensitive to oxidant damage."
        },
        {
            "id": "InternalMed_Harrison_8203",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 129-1 Red blood cell (RBC) metabolism. The Embden-Meyerhof pathway (glycolysis) generates ATP for energy and membrane maintenance. The generation of NADPH maintains hemoglobin in a reduced state. The hexose monophosphate shunt generates NADPH that is used to reduce glutathione, which protects the red cell against oxidant stress. Regulation of 2,3-bisphosphoglycerate levels is a critical determinant of oxygen affinity of hemoglobin. Enzyme deficiency states in order of prevalence: glucose 6-phosphate dehydrogenase (G6PD) > pyruvate kinase > glucose-6-phosphate isomerase > rare deficiencies of other enzymes in the pathway. The more common enzyme deficiencies are encircled."
        },
        {
            "id": "Pharmacology_Katzung_500",
            "title": "Pharmacology_Katzung",
            "content": "Glucose 6-phosphate dehydrogenase (G6PD) is the first and rate-limiting step in the pentose phosphate pathway and supplies a significant amount of reduced NADPH in the body. In red blood cells (RBCs), where mitochondria are absent, G6PD is the exclusive source of NADPH and reduced glutathione, which play a TABLE 5\u20133 Classification of G6PD deficiency (WHO Working Group, 1989)."
        },
        {
            "id": "Biochemistry_Lippincott_539",
            "title": "Biochemistry_Lippinco",
            "content": "A. Glucose 6-phosphate B. Oxidized form of nicotinamide adenine dinucleotide C. Reduced form of glutathione D. Ribose 5-phosphate Correct answer = C. Glutathione (G-SH) is essential for red cell integrity and is maintained in this reduced (functional) form by nicotinamide adenine dinucleotide phosphate (NADPH)-dependent glutathione reductase. The NADPH is from the oxidative portion of the pentose phosphate pathway. Individuals with a deficiency of the regulated enzyme of this pathway, glucose 6-phosphate dehydrogenase (G6PD), have a decreased ability to generate NADPH and, therefore, a decreased ability to keep G-SH reduced. When treated with an oxidant drug such as primaquine, some patients with G6PD deficiency develop a hemolytic anemia. Primaquine does not affect glucose 6phosphate levels. Nicotinamide adenine dinucleotide (NAD[H]) is neither produced by the pathway nor used as a coenzyme by G-SH reductase. A decrease in ribose 5-phosphate does not cause hemolysis."
        },
        {
            "id": "InternalMed_Harrison_8240",
            "title": "InternalMed_Harrison",
            "content": "epidemiology G6PD deficiency is widely distributed in tropical and subtropical parts of the world (Africa, Southern Europe, the Middle East, Southeast Asia, and Oceania) (Fig. 129-6) and wherever people from those areas have migrated. A conservative estimate is that at least 400 million people have a G6PD deficiency gene. In several of these areas, the frequency of a G6PD deficiency gene may be as high as 20% or more. It would be quite extraordinary for a trait that causes significant pathology to spread widely and reach high frequencies in many populations without conferring some biologic advantage. Indeed, G6PD is one of the best-characterized examples of genetic polymorphisms in the human species. Clinical field studies and in vitro experiments strongly support the view that G6PD deficiency 655 has been selected by Plasmodium falciparum malaria, by virtue of the fact that it confers a relative resistance against this highly lethal infection. Different G6PD variants underlie G6PD"
        },
        {
            "id": "InternalMed_Harrison_29245",
            "title": "InternalMed_Harrison",
            "content": "Historically, the GSDs were categorized numerically in the order in which the enzymatic defects were identified. They are also classified by the organs involved (liver, muscle, and/or heart) and clinical manifestations. The latter is the system followed in this chapter (Table 433e-1). The overall frequency of all forms of GSD is ~1 in 20,000 live births. Most are inherited as autosomal recessive traits; however, phosphoglycerate kinase deficiency\u2014one form of liver phosphorylase kinase (PhK) deficiency\u2014and lysosomal-associated membrane protein 2 (LAMP2) deficiency are X-linked disorders. The most common childhood disorders are glucose-6-phosphatase deficiency (type I), lysosomal acid \u03b1-glucosidase deficiency (type II), debrancher deficiency (type III), and liver PhK deficiency (type IX). The most common adult disorder is myophosphorylase deficiency (type V, or McArdle disease)."
        },
        {
            "id": "InternalMed_Harrison_4447",
            "title": "InternalMed_Harrison",
            "content": "The evaluation of the patient with anemia requires a careful history and physical examination. Nutritional history related to drugs or alcohol intake and family history of anemia should always be assessed. Certain geographic backgrounds and ethnic origins are associated with an increased likelihood of an inherited disorder of the hemoglobin molecule or intermediary metabolism. Glucose-6phosphate dehydrogenase (G6PD) deficiency and certain hemoglobinopathies are seen more commonly in those of Middle Eastern or African origin, including African Americans who have a high frequency of G6PD deficiency. Other information that may be useful includes exposure to certain toxic agents or drugs and symptoms related to other disorders commonly associated with anemia. These include symptoms and signs such as bleeding, fatigue, malaise, fever, weight loss, night sweats, and other systemic symptoms. Clues to the mechanisms of anemia may be provided on physical examination by findings of infection,"
        },
        {
            "id": "Pathoma_Husain_59",
            "title": "Pathoma_Husain",
            "content": "Principles of Neoplasia I. BASIC PRINCIPLES A. Neoplasia is new tissue growth that is unregulated, irreversible, and monoclonal; these features distinguish it from hyperplasia and repair. B. Monoclonal means that the neoplastic cells are derived from a single mother cell. C. Clonality was historically determined by glucose-6-phosphate dehydrogenase (G6PD) enzyme isoforms. 1. Multiple isoforms (e.g., G6PDA, G6PDB, and G6PDc) exist; only one isoform is inherited from each parent. 2. In females, one isoform is randomly inactivated in each cell by lyonization (G6PD is present on the X chromosome). 3. Normal ratio of active isoforms in cells of any tissue is 1:1 (e.g., 50% of cells have G6PDA, and 50% of cells have G6PD8) . 4. 1:1 ratio is maintained in hyperplasia, which is polyclonal (cells are derived from multiple cells). 5. Only one isoform is present in neoplasia, which is monoclonal. 6."
        },
        {
            "id": "Neurology_Adams_11461",
            "title": "Neurology_Adams",
            "content": "The primary abnormality in McArdle disease is a deficiency of myophosphorylase, which prevents the conversion of glycogen to glucose-6-phosphate. Phosphofructokinase deficiency (Tarui disease) interferes with the conversion of glucose-6-phosphate to glucose-1- phosphate; the defect in the latter condition is also present in red blood cells (Layzer et al). The mutations for the conditions are named above and located on different chromosomes and analysis of DNA from the patient\u2019s leukocytes can be used for genetic diagnosis. The muscle (M) subunit of the phosphofructokinase protein in Tarui disease is at fault. This defect predominates in Ashkenazi Jewish men."
        },
        {
            "id": "InternalMed_Harrison_16410",
            "title": "InternalMed_Harrison",
            "content": "The geographic distributions of sickle cell disease, hemoglobins C and E, hereditary ovalocytosis, the thalassemias, and glucose-6-phosphate dehydrogenase (G6PD) deficiency closely resemble that of falciparum malaria before the introduction of control measures. This similarity suggests that these genetic disorders confer protection against death from falciparum malaria. For example, HbA/S heterozygotes (sickle cell trait) have a sixfold reduction in the risk of dying from severe falciparum malaria. Hemoglobin S\u2013containing RBCs impair parasite growth at low oxygen tensions, and P. falciparum\u2013infected RBCs containing hemoglobins S and C exhibit reduced cytoadherence because of reduced surface presentation of the adhesin PfEMP1. Parasite multiplication in HbA/E heterozygotes is reduced at high 1372 parasite densities. In Melanesia, children with \u03b1-thalassemia appear to have more frequent malaria (both vivax and falciparum) in the early years of life, and this pattern of infection appears"
        },
        {
            "id": "Biochemistry_Lippincott_530",
            "title": "Biochemistry_Lippinco",
            "content": "Almost all G6PD variants are caused by point mutations (see p. 449) in the gene for G6PD. Some mutations do not affect enzymic activity. However, other mutations result in decreased catalytic activity, decreased stability, or an alteration of binding affinity for NADP+ or glucose 6-phosphate. [Note: Active G6PD exists as a homodimer or tetramer. Mutations at the interface between subunits can affect stability.] The severity of the disease usually correlates with the amount of residual enzyme activity in the patient\u2019s RBC. For example, variants can be classified as shown in Figure 13.12. G6PD A\u2013 is the prototype of the moderate (class III) form of the disease. The RBC contain an unstable but kinetically normal G6PD, with most of the enzyme activity present in the reticulocytes and younger RBC (Fig. 13.13). Therefore, the oldest RBC have the lowest level of enzyme activity and are preferentially removed in a hemolytic episode. Because hemolysis does not affect younger cells, the"
        },
        {
            "id": "InternalMed_Harrison_29256",
            "title": "InternalMed_Harrison",
            "content": "diagnosis Clinical presentation and abnormal plasma lactate and lipid values suggest that a patient may have GSD I, but gene-based mutation analysis provides a noninvasive means of reaching a definitive diagnosis for most patients with types Ia and Ib disease. Before the glucose-6-phosphatase and glucose-6-phosphate translocase genes were cloned, a definitive diagnosis required a liver biopsy to demonstrate a deficiency. Type III GSD (Debrancher Deficiency, Limit Dextrinosis) Type III GSD is an autosomal recessive disorder caused by a deficiency of glycogen debranching enzyme. Debranching and phosphorylase enzymes are responsible for complete degradation of glycogen. When the debranching enzyme is defective, glycogen breakdown is incomplete. Abnormal glycogen accumulates with short outer chains and resembles dextrin."
        },
        {
            "id": "InternalMed_Harrison_11511",
            "title": "InternalMed_Harrison",
            "content": "Abbreviation: G6PD, glucose-6-phosphate dehydrogenase."
        },
        {
            "id": "Neurology_Adams_7515",
            "title": "Neurology_Adams",
            "content": "Inheritance of this disorder is autosomal recessive. The biochemical abnormality consists of a defect in galactose-1-phosphate uridyl transferase as a result of a mutation in GALT. This enzyme catalyzes the conversion of galactose-1-phosphate to uridine diphosphate galactose, and three forms of the enzyme are included in newborn screening. Several forms of galactosemia have been described, based on the degree of completeness of the metabolic block and some of these are due to mutations in other galactose pathway genes. In the typical (severe) form, the onset of symptoms is in the first days of life, after the ingestion of milk; vomiting and diarrhea are followed by a failure to thrive. Drowsiness, inattention, hypotonia, and diminution in the vigor of neonatal automatisms then become evident. The fontanels may bulge, the liver and spleen enlarge, the skin becomes yellow (in excess of the common neonatal jaundice), and anemia develops. In a small number, there is thrombocytopenia with"
        },
        {
            "id": "Pediatrics_Nelson_3174",
            "title": "Pediatrics_Nelson",
            "content": "G6PD, Glucose-6-phosphate dehydrogenase. tolerated in children because of their cardiovascular reserve. Usually, children with chronic anemia will have minimal tachycardia and a flow murmur on examination. The urgency of diagnostic and therapeutic intervention, especially the use of packed RBC transfusion, should be dictated by the extent of cardiovascular or functional impairment more than the absolute level of hemoglobin. The causes of anemia often can be suspected from a careful history adjusted for the patient\u2019s age (Tables 150-1 and 150-2). Anemia at any age demands a search for blood loss."
        },
        {
            "id": "Biochemistry_Lippincott_523",
            "title": "Biochemistry_Lippinco",
            "content": "G6PD deficiency is a hereditary condition characterized by hemolytic anemia caused by the inability to detoxify oxidizing agents. G6PD deficiency is the most common disease-producing enzyme abnormality in humans, affecting >400 million individuals worldwide. This deficiency has the highest prevalence in the Middle East, tropical Africa and Asia, and parts of the Mediterranean. G6PD deficiency is X linked and is, in fact, a family of deficiencies caused by a number of different mutations in the gene encoding G6PD. Only some of the resulting protein variants cause clinical symptoms. [Note: In addition to hemolytic anemia, a clinical manifestation of G6PD deficiency is neonatal jaundice appearing 1\u20134 days after birth. The jaundice, which may be severe, typically results from increased production of unconjugated bilirubin (see p. 285).] The life span of individuals with a severe form of G6PD deficiency may be somewhat shortened as a result of complications arising from chronic hemolysis."
        },
        {
            "id": "Pediatrics_Nelson_1705",
            "title": "Pediatrics_Nelson",
            "content": "Adapted from Dale DC: Neutropenia. In Lichtman MA, Kipps TJ, Seligsohn U, et al, editors: Williams Hematology, ed 8, New York, 2010, McGraw-Hill. these genes are 16q24 for p22phox, 7q11.23 for p47phox, and 1q25 for p67phox. Glucose-6-phosphate dehydrogenase also is involved in the production of superoxide, and severe forms of glucose-6-phosphate dehydrogenase deficiency also result in CGD. Patients characteristically have lymphadenopathy, hypergammaglobulinemia, hepatosplenomegaly, dermatitis, failure to thrive, anemia, chronic diarrhea, and abscesses. Infections occur in the lungs, the middle ear, gastrointestinal tract, skin, urinary tract, lymph nodes, liver, and bones."
        },
        {
            "id": "Pediatrics_Nelson_3170",
            "title": "Pediatrics_Nelson",
            "content": "adequate marrow synthesis of red blood cells (RBCs).Vitamin B12 and folic acid deficiencies lead to macrocytic anemia. Hemolytic diseases are mediated either by disorders intrinsic or extrinsic to the RBC that increase cell destruction. The most common RBC membrane disorders are hereditary spherocytosis and hereditary elliptocytosis. In both of these disorders, abnormalities of proteins within the cytoskeleton lead to abnormal RBC shapeand function. Numerous RBC enzyme deficiencies maylead to hemolysis, but only two are common: glucose-6-phosphate dehydrogenase (G6PD) deficiency and pyruvate kinase deficiency. Immune-mediated hemolysismay be extravascular when RBCs coated with antibodiesor complement are phagocytosed by the reticuloendothelialsystem. The hemolysis may be intravascular when antibodybinding leads to complement fixation and lysis of RBCs. Available @ StudentConsult.com"
        },
        {
            "id": "InternalMed_Harrison_8237",
            "title": "InternalMed_Harrison",
            "content": "First, because males have only one G6PD gene (i.e., they are hemizy gous for this gene), they must be either normal or G6PD deficient. By contrast, females, who have two G6PD genes, can be either normal or deficient (homozygous) or intermediate (heterozygous). As a result of the phenomenon of X chromosome inactivation, heterozygous females are genetic mosaics, with a highly variable ratio of G6PDnormal to G6PD-deficient cells and an equally variable degree of clinical expression; some heterozygotes can be just as affected as hemizygous males. The enzymatically active form of G6PD is either a dimer or a tetramer of a single protein subunit of 514 amino acids. G6PDdeficient subjects have been found invariably to have mutations in the coding region of the G6PD gene (Fig. 129-5). Almost all of the approximately 180 different mutations known are single missense point mutations, entailing single amino acid replacements in the G6PD protein. In most cases, these mutations cause G6PD"
        },
        {
            "id": "InternalMed_Harrison_29260",
            "title": "InternalMed_Harrison",
            "content": "Type IX GSD (Liver Phosphorylase Kinase Deficiency) Defects of PhK cause a heterogeneous group of glycogenoses. The PhK enzyme complex consists of four subunits (\u03b1, \u03b2, \u03b3, and \u03b4). Each subunit is encoded by different genes (X chromosome as well as autosomes) that are differentially expressed in various tissues. PhK deficiency can be divided into several subtypes on the basis of the gene/subunit involved, the tissues primarily affected, and the mode of inheritance. The most common subtype is X-linked liver PhK deficiency, which is also one of the most common liver glycogenoses. PhK activity may also be deficient in erythrocytes and leukocytes but is normal in muscle. Typically, a child between the ages of 1 year and 5 years presents with growth retardation and hepatomegaly. Children tend eventually to exhibit normal growth patterns initiated by a delayed growth spurt during puberty. Liver fibrosis has been identified in some patients, including children. Levels of cholesterol,"
        },
        {
            "id": "InternalMed_Harrison_13928",
            "title": "InternalMed_Harrison",
            "content": "In untreated cases, the patient usually dies 8\u201315 days after onset. A rare presentation, fulminant RMSF, is fatal within 5 days after onset. This fulminant presentation is seen most often in male black patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and may be related to an undefined effect of hemolysis on the rickettsial infection. Although survivors of RMSF usually return to their previous state of health, permanent sequelae, including neurologic deficits and gangrene necessitating amputation of extremities, may follow severe illness. Diagnosis The diagnosis of RMSF during the acute stage is more difficult than is generally appreciated. The most important epidemiologic factor is a history of exposure to a potentially tick-infested environment within the 14 days preceding disease onset during a season of possible tick activity. However, only 60% of patients actually recall being bitten by a tick during the incubation period."
        },
        {
            "id": "Pediatrics_Nelson_3172",
            "title": "Pediatrics_Nelson",
            "content": "Family history X-linked: G6PD deficiency and genetic Autosomal dominant: spherocytosis considerations Autosomal recessive: sickle cell anemia, Fanconi anemia Family member with history of cholecystectomy (for bilirubin stones) or splenectomy at an early age Ethnicity (thalassemia in persons of Mediterranean origin; G6PD deficiency in blacks, Greeks, and people of Middle Eastern origin) Race (\u03b2-thalassemia in persons of Mediterranean, African, or Asian descent; \u03b1-thalassemia in those of African and Asian descent; SC and SS in African descent) Nutrition Cow\u2019s milk diet: iron deficiency Strict vegetarian: vitamin B12 deficiency Goat\u2019s milk diet: folate deficiency Pica: plumbism, iron deficiency Cholestasis, malabsorption: vitamin E deficiency Drugs G6PD: oxidants (e.g., nitrofurantoin, antimalarials) Immune-mediated hemolysis (e.g., penicillin) Bone marrow suppression (e.g., chemotherapy) Phenytoin, increasing folate requirements"
        },
        {
            "id": "InternalMed_Harrison_8232",
            "title": "InternalMed_Harrison",
            "content": "other glycolytic enzyme abnormalities All of these defects are rare to very rare (Table 129-4), and all cause hemolytic anemia with varying degrees of severity. It is not unusual for the presentation to be in the guise of severe neonatal jaundice, which may require exchange transfusion; if the anemia is less severe, it may present later in life, or it may even remain asymptomatic and be detected incidentally when a blood count is done for unrelated reasons. The spleen is often enlarged. When other systemic manifestations occur, they can involve the central nervous system (sometimes entailing severe mental retardation, particularly in the case of triose phosphate isomerase deficiency), the neuromuscular system, or both. This is not altogether surprising, if we consider that these are housekeeping genes. The diagnosis of hemolytic anemia is usually not difficult, thanks to the triad of normomacrocytic anemia, reticulocytosis, and hyperbilirubinemia. Enzymopathies should be considered in"
        },
        {
            "id": "InternalMed_Harrison_8242",
            "title": "InternalMed_Harrison",
            "content": "clinical manifestations The vast majority of people with G6PD deficiency remain clinically asymptomatic throughout their lifetime; however, all of them have an increased risk of developing neonatal jaundice (NNJ) and a risk of developing acute HA (AHA) when challenged by a number of oxidative agents. NNJ related to G6PD deficiency is very rarely present at birth; the peak incidence of clinical onset is between day 2 and day 3, and in most cases, the anemia is not severe. However, NNJ can be very severe in some G6PD-deficient babies, especially in association with prematurity, infection, and/or environmental factors (such as naphthalene-camphor balls, which are used in babies\u2019 bedding and clothing), and the risk of severe NNJ is also increased by the coexistence of a monoallelic or biallelic mutation in the uridyl transferase gene (UGT1A1; the same mutations are associated with Gilbert\u2019s syndrome). If inadequately managed, NNJ associated with G6PD deficiency can produce kernicterus and"
        },
        {
            "id": "Pharmacology_Katzung_504",
            "title": "Pharmacology_Katzung",
            "content": "G6PD enzyme deficiency affects over 400 million people worldwide, and the World Health Organization has categorized G6PD activity into five classes (Table 5\u20133). The majority of polymorphic G6PD-deficient genotypes are associated with class II for severe deficiency (< 10% enzyme activity) and class III for moderate deficiency (10\u201360% enzyme activity). Most individuals with reduced function alleles of G6PD have ancestries in geographical areas of the world corresponding to areas with high malaria prevalence. Polymorphic alleles gained in frequency over time as they offered some benefit against death from malaria. The estimated frequency of G6PD deficiency is approximately 8% in malaria endemic countries, with the milder G6PD-A(\u2013) allele prevalent in Africa, and the more severe G6PD-Mediterranean allele widespread across western Asia (Saudi Arabia and Turkey to India). There is a much more heterogeneous distribution of variant alleles in East Asia and Asia Pacific, which complicates G6PD"
        },
        {
            "id": "Biochemistry_Lippincott_498",
            "title": "Biochemistry_Lippinco",
            "content": "A. Glucose 6-phosphate dehydrogenation Glucose 6-phosphate dehydrogenase (G6PD) catalyzes the oxidation of glucose 6-phosphate to 6-phosphogluconolactone as the coenzyme NADP+ gets reduced to NADPH. This initial reaction is the committed, rate-limiting, and regulated step of the pathway. NADPH is a potent competitive inhibitor of G6PD, and the ratio of NADPH/NADP+ is sufficiently high to substantially inhibit the enzyme under most metabolic conditions. However, with increased demand for NADPH, the ratio of NADPH/NADP+ decreases, and flux through the pathway increases in response to the enhanced activity of G6PD. [Note: Insulin upregulates expression of the gene for G6PD, and flux through the pathway increases in the absorptive state (see p. 323).]"
        },
        {
            "id": "InternalMed_Harrison_8241",
            "title": "InternalMed_Harrison",
            "content": "655 has been selected by Plasmodium falciparum malaria, by virtue of the fact that it confers a relative resistance against this highly lethal infection. Different G6PD variants underlie G6PD deficiency in different parts of the world. Some of the more widespread variants are G6PD Mediterranean on the shores of that sea, in the Middle East, and in India; G6PD A\u2013 in Africa and in Southern Europe; G6PD Vianchan and G6PD Mahidol in Southeast Asia; G6PD Canton in China; and G6PD Union worldwide. The heterogeneity of polymorphic G6PD variants is proof of their independent origin, and it supports the notion that they have been selected by a common environmental agent, in keeping with the concept of convergent evolution (Fig. 129-6)."
        }
    ],
    "scores": [
        0.03830996531941998,
        0.034794349747574234,
        0.02792164578571222,
        0.027580890843426777,
        0.02740716293814597,
        0.02700965188911187,
        0.0264169726475271,
        0.02522045855379189,
        0.024625908598989357,
        0.024588427842495427,
        0.024568845133361262,
        0.02451984863052057,
        0.023800916597526766,
        0.0232979810374756,
        0.02326902386987363,
        0.022775240994419077,
        0.022217999391912435,
        0.02199328449328449,
        0.020954199982209747,
        0.020866114340151783,
        0.020512760951093566,
        0.020314359957030455,
        0.019482562908041075,
        0.01899189918991899,
        0.01835017019074483,
        0.01832128276422786,
        0.017849547013111172,
        0.01770873786407767,
        0.017630683575626353,
        0.017577673271143318,
        0.01738934056007227,
        0.0172823023290313
    ],
    "execution_time": 55.502496004104614
}